He's a puppet who works for Jim Cramer and is the bio writer for The Street. He's a known manipulator on more than a handful of occasions. Unfortunately, most of the stocks he writes about are written in a completely one-sided, negative view and they end up getting crushed.
He has a degree in Political Science yet somehow is a writer for pharma. I'm not sure how he got that job nor why people take him seriously, but they do and he's done serious damage on a lot of share prices over the years.
I've seen a few people tweet AMBS to him over the past year and I've told those people to #$%$ but it seems it's too late, AMBS is on his radar, for better or worse.
Amarantus Acquires Additional Rights to LymPro Test From Memory Dx
SAN FRANCISCO, May 5, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that it has acquired additional rights for its flagship Alzheimer's blood diagnostic LymPro Test ® from Memory Dx, LLC. The rights acquired by Amarantus are related to certain improvements that were sought out for the LymPro assay following the completion of work published in 2012 in the scientific journal Neurobiology of Aging. Memory Dx and Amarantus identified that these data sets fall outside the purview of Memory Dx' license agreement with the University of Leipzig, thereby allowing Memory Dx to sell the rights outright to Amarantus, without related milestones and royalties.
"With analytical performance achieved on the original LymPro assay (Version 1) published in the scientific journal Neurobiology of Aging in 2012, we are well positioned to commercialize a strong, analytically valid and well performing assay in the second half of 2014, given the work we have done with Becton Dickinson over the last year," said Gerald E. Commissiong, President & CEO of Amarantus. "The team at Memory Dx conducted a significant amount of work beyond the 2012 Neurobiology of Aging publication, and we believe certain improvements to the LymPro Test ® may be made as a result of their unpublished work (Version 2). Today's agreement positions Amarantus to have exclusivity over LymPro for the foreseeable future both in the United States and internationally as we continue negotiations with CLIA partners. Further, as we continue the build out of Amarantus Diagnostics, our diagnostic division, these additional rights coupled with plans in process to re-launch development for our NuroPro diagnostic
Gerald Commissiong @G_Commish 8m
Looking forward to next week at Cavendish to discuss our Alzheimer's Tx and Dx programs. Our Bus Dev team will be at ChinaBio. $AMBS
Expand Reply Retweeted Favorited More
I'm looking for a move this year similar to the ELTP run that we saw earlier. Ran from under a dime to almost hitting a buck.
Thanks for the reply and updates. I refuse to sell this at a loss because I know that once I do, something will happen that will cause this to move back up. Just holding and hoping at this point...
No bashing here. I'm a long sitting on a bag of useless shares and have stopped even paying attention to anything AMRN. Is there anything this year that we can look forward to as a catalyst? Please don't respond with increasing script numbers because it's clear the street doesn't care about that. I know the Kowa partnership will help increase scripts them but I'm looking for something more than this. Nor do I want to hear about buyout Sitting on an average in the mid $7s and feel like we're never going to see that again.
He doesn't have control over the stock price, nitwit. The foundation is being built and eventually we'll boom. I hope before it happens weak holders like yourself decide to sell and chase it up later.
Man, some of you guys spend way too much time on here posting utter nonsense. Wasn't that long ago that this board was clean and full of great dd. What happened...
All recent sells were set up automatically for tax purposes.
I think the problem lies in the fact that he's been tooting about it for a while now. The market wants to see proof. Once the marketing and sales plan is revealed, we should see a good move. Until then, conferences, interviews and pr's stating the same thing will move this just enough for scalpers to reap the benefit.
He's done this in the past as well. He used to write about how he just got off the phone with Gerald after a conference and stated all of the things he talked to him about (which, just like this scenario, are all updates that everyone already knows about *surprise, surprise*) but that Gerald couldn't talk long because he was on a flight to .
I think he has a Microsoft Word file that has all of his posts that he just copy and pastes from and this is how he spends his day. A couple of posts on iHub followed by a few on twitter then followed by some on Yahoo by one alias, then he logs out and into a new alias and posts using that and then does that a few times until he's going through the cycle.
Newbies in AMBS probably read what he writes and take it seriously but when they finally catch on they'll ignore him like most longs do.
It's a simple case of investors finally realizing that the pps tends to drop after conferences. Let's hope that this conference sees Gerald having more to say than the usual...
Gerald Tweet: @GianneriniPaolo I want to set proper expectations and answer questions so the market can properly evaluate Amarantus ahead of next week
Sorry for calling you nitwit in the past, it's not in my character to post such nonsense. I really have nothing against you or anyone here at all. I would like to see AMBS and all it's investors succeed.
lol... ok. I actually think I may know who he is from another message board, although he's not been on that board for the longest time.